Abstract-Interleukin-6 (IL-6) is a multifunctional cytokine expressed by angiotensin II (Ang II)-stimulated vascular smooth muscle cells (VSMCs) that functions as an autocrine growth factor. In this study, we analyze the mechanism for Ang II-inducible IL-6 expression in quiescent rat VSMCs. Stimulation with the Ang II agonist Sar 1 Ang II (100 nmol/L) induced transcriptional expression of IL-6 mRNA transcripts of 1.8 and 2.4 kb. In transient transfection assays of IL-6 promoter/luciferase reporter plasmids, Sar 1 Ang II treatment induced IL-6 transcription in a manner completely dependent on the nuclear factor-B (NF-B) motif. Sar 1 Ang II induced cytoplasmic-to-nuclear translocation of the NF-B subunits Rel A and NF-B1 with parallel changes in DNA-binding activity in a biphasic manner, which produced an early peak at 15 minutes followed by a nadir 1 to 6 hours later and a later peak at 24 hours. The early phase of NF-B translocation was dependent on weak simultaneous proteolysis of the IB␣ and ␤ inhibitors, whereas later translocation was associated with enhanced processing of the p105 precursor into the mature 50-kDa NF-B1 form. Pretreatment with a potent inhibitor of IB␣ proteolysis, TPCK, completely blocked Sar 1 Ang IIAng II-induced NF-B activation and induction of endogenous IL-6 gene expression, which indicated the essential role of NF-B in mediating IL-6 expression. We conclude that Ang II is a pleiotropic regulator of the NF-B transcription factor family and may be responsible for activating the expression of cytokine gene networks in VSMCs. (Circ Res. 1999;84:695-703.) Key Words: nuclear factor-B Ⅲ renin-angiotensin system Ⅲ angiotensin II Ⅲ cytokine A ngiotensin II (Ang II), the effector peptide of the renin-angiotensin system (RAS), is formed as a result of sequential proteolysis of the angiotensinogen precursor. Ang II is one of the most potent vasopressors known when bound to its G-protein-coupled receptor, the type 1 angiotensin receptor (AT 1 ). 1,2 In addition, Ang II promotes long-term changes in vascular smooth muscle cell (VSMC) function by its ability to induce cellular hypertrophy, 3 extracellular matrix production, 4 and early gene expression. [5] [6] [7] In this manner, Ang II regulates VSMC tone under normal conditions and mediates VSMC hypertrophy in the pathology of chronic hypertension and atherosclerosis.
A ngiotensin II (Ang II), the effector peptide of the renin-angiotensin system (RAS), is formed as a result of sequential proteolysis of the angiotensinogen precursor. Ang II is one of the most potent vasopressors known when bound to its G-protein-coupled receptor, the type 1 angiotensin receptor (AT 1 ). 1, 2 In addition, Ang II promotes long-term changes in vascular smooth muscle cell (VSMC) function by its ability to induce cellular hypertrophy, 3 extracellular matrix production, 4 and early gene expression. [5] [6] [7] In this manner, Ang II regulates VSMC tone under normal conditions and mediates VSMC hypertrophy in the pathology of chronic hypertension and atherosclerosis.
Ang II activates genetic networks in various cell types by influencing the activity and expression of nuclear regulatory proteins, including immediate-early transcription factors (activator protein 1) 5, 7 and tyrosine-receptor-coupled transcription factors (signal transducers and activators of transcription) 8 in VSMCs, early growth response-1 in cardiomyocytes, 9 and activator protein 1 in adrenal glomerulsa cells. 10 In addition, we recently reported that Ang II induces the activity of the nuclear factor-B (NF-B) transcription factor in hepatocytes. 11 NF-B is a family of cytoplasmic transcription factors composed of homodimeric and heterodimeric complexes of the potent transactivating subunits Rel A and c-Rel and the inert DNA-binding subunit NF-B1. [12] [13] [14] Rel A and c-Rel complexes are actively sequestered in the cytoplasm by association with the inhibitory proteins (IB), which inactivate the transcriptional activator subunits by binding and masking their nuclear translocation domains. After activation, NF-B translocates into the nucleus, where it binds and induces expression of cytokine and acute-phase response genes. 11, 13, 15 Although Ang II increases NF-B transcriptional activity in hepatocytes, the mechanism (and subunits affected) has not been determined, nor has it been established whether this phenomenon occurs in other cell types.
Interleukin-6 (IL-6) is a multifunctional cytokine that mediates B lymphocyte proliferation/induction of antibody synthesis and mediates the hepatic acute-phase response. 16, 17 In the vessel wall, locally secreted IL-6 also plays an important role as a VSMC growth factor through a paracrine mechanism, which involves production of PDGF. 18 -20 IL-6 is encoded by a highly inducible promoter that is a target for tissue-specific and cytokine-inducible transcription fac-tors. 16, 22 Both human and rat VSMCs inducibly secrete IL-6 in response to the inflammatory cytokines IL-1 and tumor necrosis factor (TNF), 17 bacterial cell wall-derived lipopolysaccharide, 17 platelet-derived thrombin, 21 and Ang II. 19 However, the mechanism for transcriptional activation of IL-6 in VSMCs has not been determined.
In this experiment, we examined the mechanisms for Ang II-induced activation of IL-6 gene expression in cultured rat VSMCs. Treatment with Sar 1 Ang II (100 nmol/L) rapidly activated expression of IL-6 mRNA transcripts in a transcription-dependent manner and was completely blocked by actinomycin D. In gene transfer studies with plasmids that contained the IL-6 promoter-driven luciferase reporter gene, the NF-B binding site was essential for this effect. Site mutations of the NF-B binding site blocked basal and Ang II-activated IL-6 luciferase reporter activity. Ang II induced nuclear translocation of the Rel A ⅐ NF-B1 isoforms in VSMCs concomitant with IB␣ and ␤ proteolysis. In addition, chronic Ang II stimulation induced processing of the mature form of NF-B1 (50-kDa subunit) from its 105-kDa precursor, p105. These data implicate Ang II as an activator of NF-B translocation and cytokine expression in VSMCs.
Materials and Methods

Cell Culture and Treatment
Primary cultures of rat VSMCs that expressed coupled AT 1 receptors were isolated by enzymatic dispersion and grown in DMEM as described. 23 Experiments were performed with 90% confluent cells grown on culture plates and used before passage 25. Before stimulation, cells were cultured for 72 hours in serum-free medium. In indicated locations, Sar 1 Ang II (Sigma) was added at a concentration of 100 nmol/L or recombinant human TNF-␣ (CalBiochem) was added at a concentration of 1.1 nmol/L. TPCK was from CalBiochem and used at a final concentration of 50 mol/L.
RNA Extraction and IL-6 Transcript Analysis
VSMC RNA was extracted with acid-guanidine HCl/phenol extraction (TelTex). For Northern blots, 30 g of total cellular RNA was fractionated on a MOPS/formaldehyde agarose gel as described. 15 The IL-6 cDNA probe was generated by reverse transcriptionpolymerase chain reaction (RT-PCR). 22, 24 The upstream primer for rat IL-6 was 5Ј-CAAGAGACTTCCAGCCAGTTGC-3Ј (hybridizing to nucleotides [nt] 81 to 102 of the rat mRNA) and the downstream primer was 5Ј-TTGCCGAGTAGACCTCATAGT-GACC-3Ј (hybridizing to nt 694 to 670 of the rat mRNA). The 590-bp cDNA was subcloned into the pCR2.1 plasmid (Invitrogen) and sequenced to confirm authenticity. The cDNA probe was produced in the PCR with the rat IL-6 downstream primer and [␣ 32 P] dATP. After the blots were hybridized, they were washed and exposed to a Molecular Dynamics PhosphorImager cassette for quantification.
Plasmid Construction and Transfection
The IL-6 promoter/luciferase reporter was produced with the use of the PCR with the IL-6 gene in the pGEM plasmid (a gift from S. Akira, Osaka University, Japan) as a template with the upstream primer 5Ј-TAATAAGGGATCCAATCAGCCCC ACCCGCTCT-3Ј [hybridizing to nt Ϫ310 to Ϫ279 of the gene promoter, 22 incorporating a BamH1 site (underlined)] and a downstream primer 5Ј-AAGAAGCTTGCTTCGAGGGCAGAATGAG-3Ј [hybridizing nt 25 to Ϫ3 of the gene promoter, which incorporates a HindIII site (underlined)]. The 328-bp BamH1/HindIII fragment was then subcloned into the same restriction sites of the promoterless luciferase plasmid, poLUC. 25 Site-directed mutagenesis of the NF-B site in the context of Ϫ303/ϩ23 IL-6 promoter was introduced with the technique of PCR "SOEing" 26 with the mutagenic primers (mutations underlined): ⌬ sense 5Ј-ATCAAATGTTGTATTTTACA-ATGAGTCTCAATA-3Ј, and ⌬ antisense 5Ј-ATTGAGACTCT-ATGTAAAATACAACATTTTGATAAATC-3Ј. The BamH1/HindIII fragment that contained the IL-6 promoter that mutated in the NF-B site was then subcloned into the BamH1/HindIII-digested poLUC reporter vector. Plasmids were purified by ion exchange chromatography (Qiagen) and sequenced to verify authenticity.
Transient transfections were performed by electroporation. Resuspended VSMCs (1 to 2ϫ10 7 ) were incubated for 15 minutes with 60 g of the indicated IL-6/LUC and 20 g of internal control SV40 early region promoter/alkaline phosphastase (SV2APAP) reporter plasmids on ice in a final volume of 0.5 mL of serum-free medium per cuvette, and subjected to a 35.4-to 42.1-ms pulse of 300 V and 950 mF with a Gene Pulser transfection apparatus (Bio-RAD). The transfection mixtures were incubated for another 15 minutes at room temperature before being plated onto 60-mm culture dishes. Cells were then serum-starved for 72 hours before stimulation with 100 nmol/L Sar 1 Ang II for 5 hours. In the luciferase assays, transfected cells were washed with PBS 3 times and lysed on the plate by the addition of 200 L of lysis buffer (25 mmol/L Tris-phosphate, pH 7.8; 2 mmol/L DTT; 2 mmol/L trans-1,2-diaminocyclohexane-N,N,NЈ,NЈ-tetracetic acid; 10% glycerol; 1% Triton X-100), and cytoplasmic lysates (100 L) were assayed for luciferase and alkaline phosphatase reporter activities. 27 Luciferase activity was determined by subtraction of machine background and normalization of each plate to alkaline phosphatase activity.
Western Immunoblots and Immunoprecipitation
Two to three hundred micrograms of cytoplasmic or nuclear extracts were prepared as described 28 and fractionated on SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membrane, and subjected to Western immunoblots. Primary antibodies were rabbit polyclonal anti-IB, IB␤, Rel A, c-Rel, and NF-B1 antibodies. Immune complexes were detected by binding donkey anti-rabbit IgG conjugated to horseradish peroxidase followed by reaction in the enhanced chemiluminescence assay (ECL, Amersham International). The specificity of each antibody has been documented by the ability to identify the correct molecular weight product and whether it is blocked after preadsorption with the appropriate peptide. 28 
Gel Mobility Shift and Microaffinity Purification Assays
Nuclear extracts (25 g) were incubated with 40 000 cpm of 32 Plabeled duplex NF-B binding site, 5Ј-GATCCACCACAGT-TGGGATTTCCCAACCTGACCA-3Ј, and 2 g of poly(dA-dT) in a buffer that contained 8% glycerol, 100 mmol/L NaCl, 5 mmol/L MgCl2, 5 mmol/L DTT, and 0.1 mg/mL PMSF in a final volume of 20 L for 15 minutes at room temperature. 28 The complexes were fractionated on 6% native polyacrylamide gels run in TBE buffer (25 mmol/L Tris, 25 mmol/L boric acid, 0.5 mmol/L EDTA), dried, and exposed to Kodak X-AR film at Ϫ70°C.
Microaffinity purification of NF-B binding proteins was performed with chemically synthesized oligonucleotides that contained 5Ј biotin (Bt) on a flexible linker (Genosys). Sequences of duplex oligonucleotides are WT: GATCCATCAGTTGCAAATCGTGGAATTTCCTCTA GTAGTCAACGTTTAGCACCTTAAAGGAGATCTAG ⌬B: GATCCATCAGTTGCAAATCGTTTAATTTAATCTA GTAGTCAACGTTTAGCAAATTAAATTAGATCTAG NM: GATCCATCAGCTACGAGTCGTGGAATTTCCTCTA GTAGTCGATGCTCAGCACCTTAAAGGAGATCTAG Forty picomoles of Bt oligonucleotide duplex was incubated with 800 g of nuclear extracts from VSMCs either untreated or stimulated with Ang II for the indicated time in the presence of 10 g of poly(dA-dT) in a 1-mL volume of binding buffer that contained 12.5 mmol/L HEPES (pH 7.9), 4 mmol/L MgCl 2 , 60 mmol/L KCl, 1 mmol/L EDTA, 1 mmol/L DTT, 6% glycerol, and protease inhibitor cocktail for 30 minutes at 4°C. The bound proteins were collected by the addition of 40 L of a 50% (vol/vol) slurry of streptavidin-agarose beads (Pierce) and incubation for 2 more hours at 4°C. After the binding proteins were washed 4 times with binding buffer and transferred to fresh microtubes, they were eluted in a 100-L volume a of mixture of Laemmli buffer and 500 mmol/L KCl and fractionated in SDS-PAGE for the Western immunoblotting probed with anti-Rel A or anti-NF-B1 antibodies. For competition, a 10-fold excess of nonbiotinylated oligonucleotides was included in the initial binding reaction.
Results
Ang II Activates Endogenous IL-6 Gene Expression in Quiescent VSMCs
Both human saphenous vein and rat aortic VSMCs have been previously shown to inducibly express IL-6 mRNA and protein. 17, 19, 21 To confirm that Ang II induces expression of IL-6, cell culture supernatants of quiescent VSMCs stimulated for 3 hours with Sar 1 Ang II were assayed by ELISA. During this period, untreated control cultures produced 100Ϯ80 ng/mL IL-6, whereas cells stimulated with 100 nmol/L Sar 1 Ang II accumulated 850Ϯ120 ng/mL, and those stimulated with 1 mol/L accumulated 970Ϯ120 ng/mL (meanϮSD, nϭ4 experiments, PϽ0.05 for each treatment compared with control, Student's t test). To analyze whether IL-6 secretion occurred as a consequence of increased transcript abundance, a preliminary time course with RT-PCR was performed that revealed a maximal IL-6 expression at 1 hour (not shown). To examine the magnitude of induction and determine the transcript sizes produced, Northern blot analysis was performed on VSMCs stimulated for 1 hour ( Figure  1 ). Relative to control, Sar 1 Ang II rapidly induced a 3Ϯ1-fold change in steady state IL-6 abundance (meanϮSD, nϭ3, PϽ0.05). To determine whether IL-6 induction was transcriptional, actinomycin D-pretreated cells were stimulated with Ang II (Figure 1 , right panel). Actinomycin D completely blocked IL-6 transcript accumulation. These data indicate that Ang II induces a rapid but transient transcriptional induction of IL-6 gene expression in rat VSMCs. 17 To isolate the component of IL-6 induction that was due to changes in IL-6 transcription, Ϫ303/ϩ22-bp of the IL-6 promoter/luciferase reporter (Ϫ303/ϩ22 IL-6/LUC) gene was transfected into rat VSMCs and subsequently stimulated for 5 hours with either vehicle, Sar 1 Ang II (100 nmol/L), or TNF-␣ (1.1 nmol/L). As shown in Figure 2 , normalized luciferase activity (IL-6/luciferase to internal control alkaline phosphatase) after Sar 1 Ang II stimulation increased 1.7Ϯ0.3-fold relative to control (meanϮSD, nϭ3, PϽ0.05, Student t test), whereas after stimulation with TNF-␣ increased 2.3Ϯ0.5-fold (meanϮrange, nϭ2). The role of NF-B in Ang II-induced activation of Ϫ303/ϩ22 IL-6/LUC reporter activity was assayed by introduction of a site mutation of the NF-B binding site into the Ϫ303/ϩ22 IL-6/LUC reporter (Ϫ303/ϩ22 IL-6 ⌬/LUC). After stimulation, the Ϫ303/ϩ22 IL-6 ⌬/LUC was inert to stimulation by both agents (Ang II and TNF-␣). To determine whether the NF-B binding site is sufficient to confer Ang II inducibility, we analyzed an NF-B response element in a promoter context where basal and inducible activity could be measured. In VSMCs, the IL-8 promoter is also Ang II inducible; deletion of the NF-B binding site completely blocked Ang II induction ( Figure  2B ). We have previously demonstrated that the NF-B binding site is an Ang II-inducible enhancer that can confer Ang II induction onto a heterologous promoter. 11 Although the unlikely possibility of cryptic Ang II-inducible elements in the IL-6 promoter cannot be completely excluded, we interpret these data to indicate that the NF-B binding site is necessary and sufficient for Ang II-mediated transcription.
Ang II Stimulates NF-B DNA-Binding Activity in a Biphasic Manner
To determine whether Ang II stimulates changes in NF-B DNA binding activity in VSMCs, NF-B binding was assayed in nuclear extracts from cells stimulated for various times with Sar 1 Ang II ( Figure 3A) . In unstimulated nuclei, a single binding activity was seen (complex C2), and on longer exposures, a faint binding of a slower migrating complex, C1, could be seen (not shown). In contrast, within 0.25 hours after Ang II treatment, the second complex, C1, and to a lesser extent C2 were both induced. Although C1 binding was detectable at all times after Ang II treatment (0.25 to 24 hours), its abundance was maximal at 0.25 hours, fell at 1 hour, and reaccumulated at 24 hours. Compared with control, aggregate (C1ϩC2) NF-B binding activity was increased 3.2Ϯ1.8-fold at 0.25 hours and 2.8Ϯ1.4-fold at 24 hours (meanϮSD, nϭ3, PϽ0.05 for each time point, Student t test). To exclude potential nonspecific effects for the NF-B induction at 24 hours, control experiments were performed. Cells starved for 72 hours were harvested, and NF-B binding was compared with cells starved an additional 24 hours in the absence or presence of Sar 1 Ang II ( Figure 3B ). As a positive control, cells maintained in serum-free medium for 24 hours were subsequently stimulated with TNF-␣. A strong induction of NF-B binding was observed only in the 24-hour Ang II-and 15-minute TNF-␣-treated plates, which indicates NF-B binding requires the presence of hormone.
Binding specificity for the NF-B complexes was demonstrated with competition in gel shift assay in which unlabeled oligonucleotides that represented the wild-type NF-B site (WT) and 2 unrelated mutations-(⌬B1, ⌬B2), neither of which bind to NF-B, 15 were included at a molar excess to . 28 The constitutive C2 complex and the Ang II-inducible C1 complex both compete with the wild type but not the NF-B site mutations, which indicates they are sequence-specific NF-B binding complexes.
labeled probe in the binding reaction ( Figure 3C ). Only the WT NF-B competed successfully for the binding of the C1 and C2 complexes. These data indicated that both complexes bind with NF-B specificity.
To specifically demonstrate the changes in DNA-binding activity of the Ang II-inducible NF-B subunits, we used a 2-step microaffinity isolation/Western immunoblot DNAbinding assay. 15 In this assay, nuclear proteins from control or Sar 1 Ang II-stimulated VSMCs are incubated in the presence of Bt duplex NF-B binding site (Methods), captured by the addition of streptavidin-agarose beads, and bound proteins are detected with Western blot. This assay allows the precise detection and quantification of NF-B proteins whose epitopes may be masked within the NF-B ⅐ DNA complex. 15 As shown in Figure 4A , both the 65-kDa Rel A and 50-kDa NF-B1 subunits were present and constitutively bound in unstimulated nuclei. However, the binding activity of both proteins was inducible by Ang II. Moreover, the abundance of both Rel A and NF-B1 was biphasic and was rapidly increased in Ang II-stimulated nuclei at 0.25 hours, decreased at 1 hour, and gradually reaccumulated over the next 24 hours. We note that the relative changes in Rel A and NF-B1 binding exactly paralleled the relative changes in inducible C1 complex binding in the gel shift assay ( Figure 3A ).
Sequence specificity of Rel A and NF-B1 binding activities was determined in the experiment shown in Figure 4B . In this competition assay, the Bt-duplex NF-B binding step was done in the presence of 10-fold excess of nonbiotinylated duplex WT, NF-B (⌬B), or a non-NF-B mutation (NM). Both Rel A and NF-B1 binding were competed for by the addition of the WT or the NM mutations but not the NF-B (⌬B), which indicates NF-B binding specificity.
Ang II Increases Nuclear Translocation of the 65-kDa Rel A Isoform
To confirm that the nuclear abundance of Rel A is influenced by Ang II treatment, which accounts in part for its changes in DNA-binding activity, Western immunoblots to measure Rel A abundance in cytoplasmic and sucrose cushion-purified nuclei were performed ( Figure 5, top panel) . Sixty-five kilodaltons of Rel A was predominately cytoplasmic in unstimulated cells, although a small fraction was nuclear. After Ang II treatment, cytoplasmic Rel A did not change significantly. However, nuclear Rel A rapidly increased within 0.25 hours; compared with control levels, Rel A abundance increased 3.0Ϯ1-fold (MEANϮSD, nϭ3, PϽ0.05). This indicated that although a statistically significant change in nuclear Rel A was detected, the fraction of Rel A translocated into the nucleus was only a minor fraction of the total cytoplasmic reservoir. 12, 28 More importantly, the relative steady-state changes in Rel A observed in the nuclear compartment after Ang II stimulation exactly paralleled the changes in NF-B binding ( Figures 3A and 4A ).
Ang II Increases Cytoplasmic Proteolysis of the c-Rel Isoform
In epithelial and liver cells, 15 c-Rel is a Ϸ78-kDa cytoplasmic protein that is regulated by a nuclear translocation mechanism in parallel with Rel A 28 and inducibly binds with high affinity to NF-B regulatory elements. 15, 28 Western immunoblots of cytoplasmic and nuclear fractions of Ang II-stimulated VSMCs were also analyzed for changes in c-Rel abundance ( Figure 5 ). We were surprised to observe that c-Rel disappears rapidly from both the cytoplasmic and nuclear compartments. These data indicate that Ang II induces a paradoxical disappearance of c-Rel in VSMCs.
Ang II-Induced Transient Proteolysis of the IB␣ and ␤ Isoforms
The IB isoforms ␣ and ␤ are the predominant inhibitors responsible for Rel A inactivation expressed in VSMCs. 12 To determine whether Ang II stimulation influences steady-state abundance of IB␣ and/or ␤, Western immunoblots were performed on Sar 1 Ang II-stimulated cytoplasmic extracts. Thirty-seven kilodaltons of IB␣ and 46-kDa of IB␤ were detected in control cytosolic extracts ( Figure 6A ). For IB␣, 0.25 hours after Ang II treatment, proteolysis was consistently but weakly discernible. In 3 separate experiments, IB␣ abundance was 60Ϯ25% of control values at this time point (PϽ0.05, nϭ3, Student t test). IB␤ was also proteolyzed at 0.25 hours to 70% (range 50% to 90%, nϭ2) but not thereafter. Compared with our experience of the effect of TNF-␣ on NF-B translocation and IB proteolysis in other cell systems, the effects of Sar 1 Ang II were small. To determine whether there are intrinsic differences between NF-B inducibility and that of the hormone, the effects of both hormones were analyzed ( Figure 6B ). At maximal doses of each ligand, TNF-␣ produced a greater degree of NF-B binding, Rel A translocation, and IB␣ proteolysis than produced by Sar 1 Ang II. These data indicate that TNF-␣ is a more potent activator of NF-B (and IB␣ proteolysis) than Sar 1 Ang II.
Late-Phase NF-B Induction: Ang II Increases 50-kDa NF-B1 Translocation and Processing From the p105 Precursor
NF-B1 p50 is the primary DNA binding subunit of NF-B and is a processed form of the cytoplasmic 105-kDa precursor. 30 In Figure 7A , immunoblots of cytoplasmic and sucrose cushion-purified nuclear fractions from Sar 1 Ang II-stimulated VSMCs were incubated with NH 2 -terminal anti-NF-B1 antibody to detect the precursor and mature forms. In control cells, the majority of NF-B1 was cytoplasmic, which includes discrete 105-kDa, 84-kDa, and the mature 50-kDa forms. Similar to Rel A and c-Rel, the majority of the protein was cytoplasmic, with little of the 50-kDa form being nuclear. After Ang II treatment, the abundance of 50-kDa NF-B1 increased monotonically over 24 hours. In addition, we note that the NF-B1 p105 and p84 precursors also accumulated in the nucleus.
The later increase in nuclear NF-B1 p50 may be the result of enhanced processing from the p105 precursor as suggested by the cytoplasmic accumulation of 60-kDa intermediate NF-B1 isoforms (large arrow, Figure 7A ). To help establish the latter phenomenon, immunoblots of whole-cell lysates from the same Ang II treatment times were prepared and stained with NF-B1 antibody ( Figure 7B ). The whole-cell abundance of NF-B1 p50 increased from 1 to 24 hours in parallel with the latter phase of nuclear NF-B1. These data indicate Ang II perhaps has a biphasic effect on NF-B1, initially by promoting its translocation and secondarily by increasing its processing from the p105 precursor.
Protease Inhibitors That Block NF-B Activation Also Block Ang II-Induced Endogenous IL-6 Gene Expression
Taken together, our data indicated that proteolysis of IB is required for the initial phase of Rel A NF-B1 translocation after Ang II stimulation in VSMCs. To provide additional information for this mechanism and determine the relationship of Rel A ⅐ NF-B1 translocation to endogenous IL-6 gene expression, we pretreated VSMCs with the IB proteolysis inhibitor TPCK 31 before Ang II stimulation. A gel mobility shift assay of control and Ang II-stimulated VSMCs in the absence or presence of the protease inhibitor TPCK (50 mol/L) and PMSF as a control is shown in Figure 8A . Pretreatment with TPCK but not PMSF completely blocked the appearance of inducible NF-B binding. Parallel-treated plates of VSMCs were subjected to RT-PCR to detect changes in endogenous IL-6 gene transcription ( Figure 8B ). IL-6 mRNA was induced in the Ang II-treated cells but not in Ang II-treated cells pretreated with TPCK. These data indicate that Rel A ⅐ NF-B1 translocation is required for endogenous IL-6 gene expression after Ang II stimulation.
Discussion
Ang II regulates VSMC growth and gene expression through signal transduction cascades coupled to the AT 1 . Several reports indicate that the pathological changes in the vessel wall observed as a result of atherosclerosis and hypertensive vascular injury are inflammatory in nature. Injured VSMCs phenotypically switch from a contractile to a synthetic phenotype, 32 which produces cytokines and growth factors. In this way, VSMCs assume an endocrine function in the vessel wall. Although VSMCs are highly responsive to other NF-B activators such as IL-1, TNF, and unidentified serum components, 12, 33 we report in this study for the first time that Ang II is also a pleiotropic activator of the NF-B transcription factor family in VSMCs, one of whose function is to induce the secretion of the acute-phase mediator and vascular growth factor IL-6. The relationship of NF-B activation to IL-6 is based on the observations that (1) Ang II induces NF-B binding in parallel with IL-6 gene transcription, (2) site mutations of the NF-B binding site block both basal and inducible IL-6 expression, (3) inhibition of NF-B translocation by the proteasome inhibitor blocks endogenous IL-6 expression, and (4) NF-B is an Ang II-inducible cis regulatory element (Figure 2 and Reference 11). These data provide an important link among the activated RAS, inflammatory response, and VSMC hypertrophy in the vessel wall.
NF-B in both human and rat VSMCs is an inducible complex composed of Rel A ⅐ NF-B1 (p50) heterodimers whose increased nuclear binding is mediated through a process that involves cytoplasmic-nuclear translocation (this study and 12). After Ang II treatment of VSMCs, we observe a biphasic pattern of activation of Rel A ⅐ NF-B1 heterodimers, with a rapid early activation (0.25 hours), followed by a variable nadir (1 to 2 hours), and a late activation (6 to 24 hours). The early activation is simultaneous with a weak degree of IB␣ and ␤ proteolysis in the cytoplasm. The late activation phase primarily occurs as a result of enhanced processing of the NF-B1 p105 precursor into the mature 50-kDa nuclear DNA-binding subunit. Both IB proteolysis and p105 processing are mediated by the ubiquitinproteasome pathway 31 ; together these observations indicate that Ang II induces intracellular proteolysis of various NF-B isoforms through the 26S proteasome. Taken together, these data implicate a pleiotropic effect of Ang II on members of the NF-B-IB family. The early phase of Rel A ⅐ NF-B1 translocation is associated with IL-6 gene expression (measured by Northern blot) and transcriptional activity (measured by transfection assay). However, after 24 hours, IL-6 mRNA Western immunoblotting from 250-g cytoplasmic (left) and 300-g nuclear (right) extracts of VSMCs treated with Sar 1 Ang II for indicated times (in hours, top) with anti-NF-B1 primary antibody. The 105-kDa NF-B1 precursor (p105), the alternatively spliced 84-kDa NF-kB1 precursor (p84, asterisks), 2 Ϸ60-kDa NF-B processing intermediates (large and small arrow), and the mature 50-kDa NF-B1 (NF-B1) are indicated. In control cells, the majority of NF-B1 p105, p84, and p50 are cytoplasmic. After Ang II treatment, there is accumulation of the 60-kDa NF-B1 intermediate (large arrow). In the nuclear compartment, after Ang II treatment, NF-B1 p50 is rapidly translocated, whereas the p105 precursor is translocated later (1 to 6 hours) along with the NF-B1 p84 isoform. B, Enhanced abundance of NF-B1 in whole lysates of Ang II-treated VSMCs. Western immunoblotting from 200-g whole-cellular lysates of VSMCs treated with Ang II for indicated times (in hours, top) with anti-NF-B1 primary antibody.
is no longer expressed even though NF-B binding activity is detectable. Together, these data probably indicate that the IL-6 gene may be actively repressed (after its activation) in a manner dominant to NF-B binding.
Other investigators have shown that in VSMCs, the effect of NF-B-inducing hormones on steady-state levels of the IB inhibitors is not equivalent. For example, the cytokine IL-1␤ induces a pattern of sequential IB proteolysis, with a rapid IB␣ proteolysis (at 30 minutes) followed by a later IB␤ proteolysis (2 hours), which results in a sustained profile of nuclear Rel A ⅐ NF-B1 binding. 12 The IL-1-like cytokine TNF-␣ only induces IB␣ but not IB␤ proteolysis and only a transient pattern of NF-B binding. 12 In this study we observe that at maximal agonist doses, Sar 1 Ang II and TNF-␣ induce IB␣ proteolysis to a different extent, with Ang II inducing a combined (weak, but statistically significant) IB␣ and IB␤ proteolysis. These data indicate that the IB molecules are subject to differential hormonal regulation by Ang II and cytokines in VSMCs.
Our data also implicate a delayed effect of Ang II on NF-B1 processing in VSMCs. NF-B1 p50 is the NH 2 -terminal DNA-binding product of p105 precursor processing. 30 The proteolyzed COOH terminal region of p105 contains repeated domains homologous to erythrocyte ankyrin and functions as an IB-like molecule retaining Rel A and/or c-Rel in the cytoplasm. 34 In various cell types, p105 is inducibly phosphorylated and proteolyzed through a midmolecule glycine-rich region. 31 After p105 processing, sequestered Rel A and NF-B1 DNA-binding subunits are released for subsequent translocation into the cell nucleus. Our data indicate that NF-B1p105 is not only inducibly processed but also undergoes nuclear translocation 6 hours after Ang II stimulation. We do not believe that this is due to cytoplasmic contamination of our nuclear preparations because our highly purified nuclei (prepared by sucrose cushion centrifugation) are devoid of cytoplasmic markers. 28 Cytoplasmic-nuclear translocation of p105 has not been described in VSMCs. However, in Epstein barr virus-infected B lymphocytes, NF-B1 p105 was observed to be nuclear and processed within the nucleus. 39 One welldescribed activator of NF-B processing is the potent protein kinase C agonist phorbol 12-myristate 13-acetate. 35 It is noteworthy that Ang II is a potent activator of protein kinase C; we speculate that this may be a common pathway used in Ang II induction of NF-B1 processing.
c-Rel is a transactivating protein found in cytokineinducible NF-B complexes in epithelial cells 15 whose nuclear-cytoplasmic translocation is also controlled by complex with IB␣ and IB␤. 36 -38 A surprising observation in this study is that cytoplasmic c-Rel is proteolyzed after Ang II treatment and not translocated into the nucleus. c-Rel has been implicated in growth arrest at the G1/S-phase boundary 39 ; we speculate its proteolysis may be required for Ang II-induced activation of quiescent VSMCs. 3 Within the context of the atheromatous arterial wall, a variety of NF-B activators have been identified, including cytokines, IL-1, TNF-␣, thrombin, and oxidized LDL, 12, 32, 40 that act on endothelial, macrophage, T-lymphocyte, and smooth muscle cells to express genes important in the fibroproliferative response, including vascular cell adhesion molecule-1 tissue factor, colony stimulating factors, and chemotactic cytokines. These factors function in a paracrine way on resident cells to facilitate intercellular interactions and amplify the inflammatory response. We propose that Ang II, the central effector molecule of the activated RAS, also participates in the phenotypic switch of VSMCs into cells with endocrine functions, thereby producing IL-6 and perhaps other NF-B-regulated genes. Within the vessel wall, IL-6 is likely to play several important roles. Although IL-6 is an activator of acute-phase reactant expression in liver cells and antibody production in B lymphocytes, IL-6 functions as an autocrine growth factor in VSMCs through its ability to influence PDGF expression. 20 Additionally, IL-6 may also play an important chemotactic role in stimulating progenitor cells that have transmigrated through the activated endothelium. 16 In summary, Ang II the octapeptide effector of the activated RAS, mediates IL-6 expression in VSMCs through pleiotropic effects on the NF-B family of transcriptional regulators. These observations further underscore the link between the activated RAS and inflammatory cytokine expression or activation in the vascular wall. Figure 8A for 1 hour. Shown is an ethidium bromidestained cDNA product (top with IL-6 primers, bottom with ␤-actin primers) after agarose gel electrophoresis. TPCK pretreatment completely blocks inducible IL-6 gene expression.
